ArticleCirculation reports2019

Safety and Efficacy of Ambrisentan-Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice.

Masaharu Kataoka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.